In The News
Firm fees, funder’s cut slashed in $180M stolen wages class action settlement
Clayton Utz got biggest slice of government’s $600M legal spend
Lander & Rogers denies taking adverse action against wheelchair user
Keybridge shareholder can sue over $4.75M advance for Lake Como property
Real estate ‘mogul’ Sasha Hopkins slapped with $1.25M fine
Supermarkets to face $10M fines for industry code breaches
MinterEllison hires regulatory lawyer from Herbert Smith Freehills
Google faces potential class action over AdTech dominance
High Court cases could push Blue Sky class action trial to 2026
Dominique Grubisa’s companies illegally scraped court websites: OAIC
Please login to bookmarkClose

The ACCC has refused to authorise a patent settlement and license agreement between Bristol-Myers Squibb unit Celgene and two generic drug makers who sued to invalidate the patents for its blockbuster cancer drug Revlimid, saying it could distort competition between generic drug makers.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au